| Literature DB >> 35505819 |
Ronit Patnaik1, Eugenia Tsai1,2.
Abstract
Hepatitis C virus (HCV) infection is a common indication for liver transplantation. If the patient's HCV is untreated prior to liver transplant, infection of the allograft is nearly universal and can lead to graft failure. The demand for deceased-donor organ transplantation continues to surpass the available supply of donor organs. Waitlist mortality remains an important concern, and several strategies have been enacted to increase organ supply, such as using high-risk donors, including those who are HCV positive. The development of safe and highly effective HCV therapy with direct-acting antiviral agents has revolutionized the management of liver transplant candidates and transplantrecipients. Moreover, thenewer antiviral therapieshave paved the road for use of HCV-viremic organs, effectively expanding the donor pool and changing the landscape of solid organ transplantation. This article reviews the data on HCV treatment prior to and after organ transplantation.Entities:
Keywords: Chronic hepatitis C virus; direct-acting antiviral; hepatitis C virus–positive donor; liver transplantation; solid organ transplantation
Year: 2022 PMID: 35505819 PMCID: PMC9053510
Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN: 1554-7914